Companies › Ipsen
8 active drug programs in 42 registered trials: 13 Phase 3, 13 Phase 2, 8 Phase 1, 8 Phase 4; Oncology, Neurology, Immunology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Botulinum Toxin Type A Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | SNAP25 | Phase 3 | Chronic Migraine; Episodic Migraine; Obstructed Defaecation Syndrome; Rhizarthrosis … | Nov 2026 |
| Corabotase (IPN10200) | – | Phase 3 | Moderate to Severe Glabellar Lines; Cervical Dystonia; Episodic Migraine; Moderate to Severe Upper Facial Lines … | Dec 2026 |
| Elafibranor Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor delta agonist | PPARA, PPARD | Phase 3 | Primary Biliary Cholangitis; Primary Biliary Cirrhosis; Primary Biliary Cholangitis (PBC); Primary Sclerosing Cholangitis | Dec 2026 |
| IPN01194 | – | Phase 1 | Melanoma | Mar 2028 |
| IPN01195 | – | Phase 1 | Advanced Solid Tumor | Apr 2028 |
| IPN60300 | – | Phase 1 | Locally Advanced Solid Tumor | Oct 2028 |
| Tovorafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 1 | Low-grade Glioma | Jul 2030 |
| IPN01203 | – | Phase 1 | Advanced Solid Tumor | Jul 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06804993 | Botulinum Toxin Type A | Phase 4 | Obstructed Defaecation Syndrome | Gastroenterology | Sep 2023 |
| NCT06814288 | Botulinum Toxin Type A | Phase 2 | Keloid Scars | Immunology | Feb 2025 |
| NCT06814535 | Botulinum Toxin Type A | Phase 2 | Patients with Jaw Muscles Myofascial Pain | Other | Mar 2025 |
| NCT04829565 | Botulinum Toxin Type A | Phase 4 | Rhizarthrosis | Other | May 2025 |
| NCT04630873 | Botulinum Toxin Type A | Phase 1 | Post Stroke Spastic Hemiplegia | Neurology | Aug 2025 |
| NCT06583590 | Botulinum Toxin Type A | Phase 2 | Erectile Dysfunction With Diabetes Mellitus | Metabolic and endocrine | Aug 2025 |
| NCT03944876 | Botulinum Toxin Type A | Phase 3 | Cluster Headache | Neurology | Sep 2025 |
| NCT06734598 | Botulinum Toxin Type A | Phase 4 | Trismus | Oncology | Nov 2025 |
| NCT05990881 | Botulinum Toxin Type A | Phase 3 | Carpometacarpal Sprain | Infectious disease | Dec 2025 |
| NCT06839118 | Botulinum Toxin Type A | Phase 3 | Posttraumatic Headache | Psychiatry | Mar 2026 |
| NCT06878482 | Botulinum Toxin Type A | Phase 4 | Chronic Ulcer of Lower Extremity | Immunology | Mar 2026 |
| NCT06047444 | Botulinum Toxin Type A | Phase 3 | Chronic Migraine | Neurology | Nov 2026 |
| NCT06047457 | Botulinum Toxin Type A | Phase 3 | Episodic Migraine | Neurology | Nov 2026 |
| NCT07082972 | Botulinum Toxin Type A | Phase 4 | Myofascial Pain Syndrome (MPS) | Other | Dec 2026 |
| NCT07427797 | Corabotase (IPN10200) | Phase 3 | Moderate to Severe Glabellar Lines | Other | Dec 2026 |
| NCT07435428 | Corabotase (IPN10200) | Phase 3 | Moderate to Severe Glabellar Lines | Other | Dec 2026 |
| NCT07847541 | Botulinum Toxin Type A | Phase 2 | Temporomandibular Disorder | Other | Dec 2026 |
| NCT06730061 | Elafibranor | Phase 3 | Primary Biliary Cholangitis | Gastroenterology | Dec 2026 |
| NCT06296082 | Botulinum Toxin Type A | Phase 2 | Stroke | Neurology | Dec 2026 |
| NCT06448676 | Botulinum Toxin Type A | Phase 4 | Wrinkle | Other | Jan 2027 |
| NCT07399860 | Botulinum Toxin Type A | Phase 2 | Hemorrhoids | Other | Jan 2027 |
| NCT06411028 | Botulinum Toxin Type A | Phase 4 | Dystonic Tremor Syndrome | Neurology | Jan 2027 |
| NCT07880860 | Botulinum Toxin Type A | Phase 2 | Cleft Lip | Other | Feb 2027 |
| NCT06937931 | Corabotase (IPN10200) | Phase 2 | Cervical Dystonia | Neurology | Mar 2027 |
| NCT03198702 | Botulinum Toxin Type A | Phase 3 | Obstetrical Brachial Plexus Palsy | Other | Jun 2027 |
| NCT04821089 | Corabotase (IPN10200) | Phase 1 | Moderate to Severe Upper Facial Lines | Immunology | Aug 2027 |
| NCT05720065 | Botulinum Toxin Type A | Phase 2 | Temporomandibular Disorders | Other | Aug 2027 |
| NCT06625060 | Corabotase (IPN10200) | Phase 2 | Episodic Migraine | Neurology | Oct 2027 |
| NCT02216838 | Botulinum Toxin Type A | Phase 4 | Facial Flushing | Other | Dec 2027 |
| NCT06721520 | Botulinum Toxin Type A | Phase 2 | Esophageal Cancer Surgery | Gastroenterology | Dec 2027 |
| NCT06305247 | IPN01194 | Phase 1 | Melanoma | Oncology | Mar 2028 |
| NCT06833008 | IPN01195 | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2028 |
| NCT07779252 | Corabotase (IPN10200) | Phase 3 | Moderate to Severe Glabellar Lines | Other | Apr 2028 |
| NCT07894991 | Botulinum Toxin Type A | Phase 2 | Spinal Cord Injury | Neurology | Apr 2028 |
| NCT07213817 | IPN60300 | Phase 1 | Locally Advanced Solid Tumor | Oncology | Oct 2028 |
| NCT04526665 | Elafibranor | Phase 3 | Primary Biliary Cirrhosis | Gastroenterology | Dec 2028 |
| NCT04752774 | Corabotase (IPN10200) | Phase 1 | Spasticity | Neurology | Mar 2029 |
| NCT06016842 | Elafibranor | Phase 3 | Primary Biliary Cholangitis (PBC) | Gastroenterology | May 2029 |
| NCT07441707 | Tovorafenib | Phase 1 | Low-grade Glioma | Oncology | Jul 2030 |
| NCT07387549 | Elafibranor | Phase 3 | Primary Sclerosing Cholangitis | Gastroenterology | Apr 2031 |
| NCT05627362 | Elafibranor | Phase 2 | Primary Sclerosing Cholangitis | Gastroenterology | Sep 2031 |
| NCT07213830 | IPN01203 | Phase 1 | Advanced Solid Tumor | Oncology | Jul 2032 |
Roche RDC Clinical Day One Biopharmaceuticals Novartis Hanmi Pharmaceutical Company Pfizer Inventiva Pharma AbbVie Erasca Pierre Fabre Medicament
Day One Biopharmaceuticals Suzhou Zelgen Biopharmaceuticals Pierre Fabre Medicament Hansoh BioMedical R&D Company Philogen
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.